Zealand Pharma A/S
ZEAL.CO
Get informed when a big investor buys or sells
+ FollowMarket Cap$16.31B
Close$
Share Statistics
| Market cap | $16.31 Billion |
|---|---|
| Enterprise Value | $12.70 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $91.56 |
| Beta | 0.61 |
| Outstanding Shares | 70,348,419 |
Return
| Return on Equity | 15.20% |
|---|---|
| Return on Assets | 13.84% |
| Return on Invested Capital | 13.27% |
Valuation & Multiples
| P/E Ratio | 6.11 |
|---|---|
| PEG | -12.6 |
| Price to Sales | 3.66 |
| Price to Book Ratio | 0.94 |
| Enterprise Value to Revenue | 2.75 |
| Enterprise Value to EBIT | 5.21 |
| Enterprise Value to Net Income | 4 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$0.92
Average shareholder expectationRevenue Estimate
$4.54 B
Average shareholder expectationNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
$-9.63
Average shareholder expectationRevenue Estimate
$101.96 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Zealand Pharma A/S.
578 employees
CEO: Emmanuel Dulac Zealand Pharma A/S is a Danish biotechnology firm dedicated to the identification, progression, and market introduction of peptide-based therapeutics. The company concentrates its efforts on treatments for gastrointestinal and metabolic ...